Use of varenicline and bupropion, medication to help quit smoking, is unlikely to be associated with increased risks of cardiovascular (CV) and neuropsychiatric adverse events compared with nicotine replacement therapy (NRT) in smokers with chronic obstructive pulmonary disease (COPD), in contrast to previous belief.
Achieving a stringent glycated haemoglobin (HbA1c) goal of <6.5 percent within 6 months of metformin initiation was associated with a decreased risk of cardiovascular (CV) events and mortality in real-world patients with type 2 diabetes, with a greater magnitude of HbA1c reduction being predictive of a lower outcome risk, according to a large Danish registry-based study.
The Micra leadless transcatheter pacing system (TPS) demonstrates a high implant success rate of 99.6 percent with low major complication rate at 30 days after implantation in real-world patients, which appears to surpass its performance observed in the IDE* trial that drove its approval, according to an interim analysis of an ongoing prospective postapproval registry.
Pioglitazone may effectively reduce the risk of acute coronary syndrome (ACS) following a cerebrovascular event among patients with insulin resistance (IR) but without diabetes mellitus, with the most prominent effect observed on spontaneous type 1 myocardial infarctions, according to a secondary analysis of the IRIS* trial.
Calcium channel blockers (CCBs) and angiotensin receptor blockers (ARBs) may protect the elderly from dementia, a retrospective analysis has shown. [J Hypertens 2017, doi: 10.1097/HJH.0000000000001411]
Adiposity appears to mediate the association between cardiorespiratory fitness and blood pressure in young adults, according to a study said to be the first to examine such relationship using mediation analysis.
A strategy of aggressive blood pressure (BP) treatment in atrial fibrillation (AF) patients scheduled to undergo catheter ablation does not appear to provide any benefit in terms of reducing atrial arrhythmia recurrence after catheter ablation, rather resulting in more adverse events (AEs) such as hypotension, a study has shown.
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Doctors uncertain on which cardiovascular (CV) risk calculator to use may consider opting for the Framingham General CV Disease risk scoreas studies have been performed in the country to validate it, says an expert.